Journal article
Evidence that the MEK/ERK but not the PI3K/Akt pathway is required for protection from myocardial ischemia-reperfusion injury by 3′,4′-dihydroxyflavonol
CJ Thomas, NR Lim, A Kedikaetswe, YY Yeap, OL Woodman, DCH Ng, CN May
European Journal of Pharmacology | ELSEVIER | Published : 2015
Abstract
The novel pro-drug of 3′4′-dihydroxyflavonol, NP202, potently reduces myocardial infarct size resulting from ischemia-reperfusion (I/R) through mechanisms that remain to be fully defined. In this study, we investigated whether cardioprotection induced by NP202 depended on activation of the reperfusion injury survival kinase (RISK) pathways. We therefore examined the effects of PD98059 and LY294002, specific inhibitors of the MEK/ERK1/2 and PI3K/Akt pathways, respectively. In isolated cardiomyocytes, H2O2induced oxidative stress activated ERK1/2 and this was further enhanced by DiOHF, the active parent compound of NP202. Although oxidative stress did not stimulate Akt in cardiomyocytes, co-tr..
View full abstractRelated Projects (1)
Grants
Awarded by Australian Research Council
Funding Acknowledgements
This work was supported by a Grant in Aid from the National Heart Foundation of Australia (G 08M 3761). CNM is supported by a Research Fellowship from the National Health and Medical Research Council of Australia NHMRC ID, (566819). DCHN is supported by an Australian Research Council Future Fellowship (FT20100193).